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Introduction: Localized scleroderma is an inflammatory disease in its first stages and a fibrotic process in later
stages, principally mediated by the transforming growth factor β. To date, there is no standard treatment. The
objective of this study was to determine the effectiveness and safety of 8% pirfenidone gel in patients with
localized scleroderma.
Methods: This was an open phase II clinical trial that included 12 patients. Treatment with pirfenidone was
indicated, three times daily for 6 months. Patients were evaluated clinically with the modified Localized
Scleroderma Skin Severity Index (mLoSSI), as well with a durometer and histologically using hematoxylin and eosin
stain and Masson’s trichrome stain.
Results: The baseline mLoSSI average scores were 5.83 ± 4.80 vs. 0.83 ± 1.75 (P = 0.002) at 6 months. The initial
durometer induration of the scleroderma plaques was 35.79 ± 9.10 vs. 32.47 ± 8.97 at 6 months (P = 0.05). We
observed histopathological improvement with respect to epidermal atrophy, inflammation, dermal or adipose tissue
fibrosis and annex atrophy from 12.25 ± 3.25 to 9.75 ± 4.35 (P = 0.032). The 8% pirfenidone gel application was well
tolerated, and no side effects were detected.
Conclusions: This is the first study on the therapeutic use of pirfenidone gel in localized scleroderma. It acts on
both the inflammatory and the fibrotic phases. Considering its effectiveness, good safety profile and the advantage
of topical application, pirfenidone is a treatment option in this condition.Introduction
Localized scleroderma is a disease with no known cause
and varied clinical expression that is characterized by scler-
osis of the skin [1]. Its pathogenesis is centered on auto-
immune alterations with a distinctive cytokine profile. It is
an inflammatory disorder during its first stages, evolving to
a fibrotic process principally mediated by tumor necrosis
factor α (TNF-α), transforming growth factor β (TGF-β),
connective tissue growth factor (CTGF) and platelet-
derived growth factor (PDGF) [2]. There is no standard
treatment for this disease, but the actual tendency suggests
that treatments based on pathogenesis are preferable [2].
Pirfenidone is a molecule derived from pyridone (5-me-
thyl-1-phenyl-2-[1H]-pyridone) and has been used as an
antifibrotic agent [3]. Its capacity to suppress the expression* Correspondence: albtlacuilo@yahoo.com
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article, unless otherwise stated.of the TGF-β gene at the transcriptional level has been
demonstrated, along with a dose-dependent reduction of
collagen types I and III mRNA levels [4,5]. Also, it can
affect the cascade of the inflammatory and fibrotic pro-
cesses, suppressing TNF-α induction, a fundamental mol-
ecule in inflammatory and immunological processes [6]. In
general, the safety profile of pirfenidone is favorable, and
significant toxicity has not been reported [7,8].
Taking into account these anti-inflammatory and
antifibrotic properties, our objective was to evaluate the
safety and effectiveness of 8% pirfenidone gel in patients
with localized scleroderma.
Methods
This study was an open phase II clinical trial approved by
the local ethics and research committee of the Instituto
Dermatologico de Jalisco. Patients included both sexes,
were 18 years old or older and had a clinical and histo-
pathological diagnosis of active localized scleroderma andioMed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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to the study, respectively. Patients gave their informed
consent to participate, a case history was taken and the
following assessments were done: (1) modified Localized
Scleroderma Skin Severity Index (mLoSSI) [9], (2) cutane-
ous induration, (3) visual analogue scale, (4) punch biopsy
and (5) safety evaluation.
Assessments
Modified Localized Scleroderma Skin Severity Index
The mLoSSI is a 0- to 162-point scale (the higher the
score, the greater the severity). It includes an evaluation
of erythema, cutaneous density and presence of new le-
sions or extension of the previous ones, using a scale of
1 to 3. A basal evaluation was done and then repeated at
3 and 6 months of treatment.
Cutaneous induration
Cutaneous induration was measured with a durometer
(Rex Gauge Type 00; Rex Gauge, Buffalo Grove, IL,
USA) [10,11] using a 0 to 100 durometer unit (DU)
scale, with a higher score indicating greater induration.
Three evaluations were done on each lesion, at three dis-
tinct points, and the average of the measurements was
used for the analysis. The measurements were also done
on an unaffected contralateral area, with a basal evalu-
ation and repeated at 3 and 6 months of treatment as a
quality control measure.
Visual analogue scale
For the patient’s evaluation of the effectiveness of treat-
ment, we used a visual analog scale (VAS), which gives a
score of 0 to 10 with respect to skin hardness andTable 1 Histological assessment criteriaa
Epidermal atrophy
Normal 0 More than seven layers
Light 1 Six to seven layers
Moderate 2 Four to five layers
Severe 3 Three layers or less
Dermal and subcutaneous infiltration
Normal 0 Absence
Light 1 Isolated lymphocytes
Moderate 2 Small groups of lymphocytes
Severe 3 Large groups of lymphocytes
Adipose tissue fibrosis
Normal 0 Absence
Light 1 Light thickening of adipose septa
Moderate 2 Moderate thickening of adipose septa
Severe 3 Severe thickening of adipose septa
aMicroscopic characteristics that were used as parameters to evaluate the effectivenpresence of itchiness, where 0 is the absence of symp-
toms and 10 is the maximum perception of these symp-
toms. This was done at the beginning and end of
treatment.
Punch biopsy
Punch biopsies were performed at the start and end of
treatment. The final biopsy was done next to the initial
biopsy position. The obtained tissue was stained with
hematoxylin and eosin stain and Masson’s trichrome stain,
with a blind examination by an expert pathologist. The
evaluated parameters included epidermal atrophy; papillary
dermis, reticular dermis or adipose tissue fibrosis; and at-
rophy of the annexes. A semiquantitative, four-grade scale
was designed: 0 = normal, 1 = slight, 2 =moderate and 3 =
severe. Table 1 lists microscopic characteristics that were
used as parameters to evaluate the effectiveness of pirfeni-
done on localized scleroderma lesions.
Safety evaluation
For the safety evaluation, laboratory tests were done
(complete blood count, liver function tests and blood
chemistry) to obtain basal levels, and then these tests
were repeated at the first, third and sixth months of
treatment and compared with baseline values. Local side
effects, adverse clinical events and abnormal laboratory
results were evaluated at the beginning and at 1, 3 and 6
months of treatment.
Treatment
Patients were instructed to apply 8% pirfenidone gel
three times daily for 6 months using the standard finger-
tip unit (0.5 g for an area of 100 to 120 cm2) [12].Papillary dermis fibrosis
Normal 0 Absence
Light 1 Reduction in thickness of lax tissue
Moderate 2 Segmental hyalinization
Severe 3 Complete hyalinization
Reticular dermis fibrosis
Normal 0 Absence
Light 1 Small pockets of hyalinization
Moderate 2 Presence of moderate hyalinization
Severe 3 Total hyalinization
Annex atrophy
Normal 0 Absence
Light 1 Periadnexal fibrosis
Moderate 2 Reduction in size of annexes
Severe 3 Presence of adnexal vestiges
ess of pirfenidone on localized scleroderma lesions.
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Statistical analysis was done with SPSS version 19.0 soft-
ware (IBM, Armonk, NY, USA). The Wilcoxon rank-sum
test was used to compare the pre- and posttreatment
evaluations. A P-value <0.05 was considered statistically
significant.
Results
A total of 12 patients with localized scleroderma were
included, 9 (75%) of whom were women and 3 (25%) of
whom were men. Their mean age was 46 years old. Cir-
cumscribed, localized scleroderma was present in three
(25%) patients, linear in three (25%) patients and the
generalized variant in six (50%) patients. The sizes of the
lesions ranged from 0.3 cm2 to 765 cm2 (Table 2).
All patients showed a sustained improvement in their le-
sions throughout the study. The basal mLoSSI average was
5.83 ± 4.80 vs. 1.33 ± 1.92 at 3 months of treatment (P =
0.003) vs. 0.83 ± 1.75 at 6 months (P = 0.002) (Figures 1 and
2, Table 3). The induration of the scleroderma lesion com-
pared with the induration of the contralateral area, which
served as a control, had a mean basal measurement of
35.79 ± 9.10 DU (24.18 to 56.73 DU) vs. 26.86 ± 8.51 DU
(13.06 to 41.36 DU) for normal skin. At 3 months of
treatment, the mean was 33.80 ± 7.24 DU (18.74 to 42.81
DU) vs. 26.90 ± 7.24 DU (12.38 to 35.03 DU) for normal
skin (P = 0.919), and the mean at the end of treatment was
32.47 ± 8.97 DU (13.51 to 49.12 DU) vs. 27.06 ± 8.50 DU
(10.85 to 38.56 DU) of normal skin (P = 0.386).
Patients’ assessments of hardness of the lesions and pres-
ence of pruritus showed improvement with the applicationTable 2 Epidemiological dataa
Patient Sex Age (yr) Time of evolution (yr) Previous treatment
1 F 47 10 Yes
2 F 24 1.5 No
3 F 77 3 Yes
4 F 66 6 Yes
5 F 54 3 Yes
6 F 29 3 Yes
7 F 21 10 Yes
8 M 31 8 No
9 M 39 3 Yes
10 F 46 2 Yes
11 M 51 <1 No
12 F 48 4 No
Mean NA 46.5 3 NA
Maximum NA 77 10 NA
Minimum NA 21 1.5 NA
aThe patients were predominately female (75%) and had received previous treatme
Not applicable.of pirfenidone, although the difference was not significant
(Table 3). At the beginning of the study, nine (75%) of the
twelve patients stated that they had skin hardness, and, of
these nine, one (8.3%) (patient 1 with linear scleroderma)
felt that the hardness had worsened and another (8.3%)
did not detect any improvement (patient 12 with gene-
ralized scleroderma). Eight (66.6%) patients reported prur-
itus, and one (8.3%) indicated worsening at the end of the
study (patient 1). The mean basal global score for the
histopathological alterations was 12.25 ± 3.25 (5 to 17) vs.
9.75 ± 4.35 (3 to 14) at 6 months of treatment (P = 0.032)
(Figure 3, Table 4).
The reported local side effects after applying pirfenidone
were present in 11 patients (92%). These included slight,
short-term burning sensation, which subsided after using
a common lubricant, with no need to suspend or reduce
the medication dosage. Additionally, there were no statisti-
cally significant changes in the laboratory tests before and
after treatment.
Discussion
It is difficult to assess the effectiveness of pharmacological
agents in localized scleroderma, owing to various factors:
rareness of the disease, heterogeneity of its severity in
different population studies, difficulty in establishing con-
trols, diverse modes of evaluation for improvement and
absence of serological markers for activity [2,13,14].
Taking this into account, we decided to assess the
therapeutic effectiveness of 8% pirfenidone gel using sev-
eral evaluation tools that allowed us to demonstrate its






Linear 10.5 97.5 1
Linear 1.5 17.5 1
Generalized 1 412.5 6
Generalized 2 255 5
Generalized 31.5 448 3
Circumscribed 360 765 2
Circumscribed 45 52.2 1
Circumscribed 0.48 7 1
Generalized 0.25 136 13
Circumscribed 12 22.5 1
Generalized 1 36 3
Generalized 6 189 2
NA 4 116.75 2
NA 360 765 13
NA 0.25 7 1
nt (67%), and one-half (50%) had the generalized type of the disease. NA,
Figure 1 Clinical changes before and after treatment. (a) Note the ivory-white color at the beginning of the treatment. (b) Reduction in color
and size at the end of treatment.
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using a durometer, as well as with improvement in both
the histopathological changes and (VAS) score, instru-
ments that had not been used together as a set in previ-
ous studies.
The improvement in the localized scleroderma lesions
with the application of 8% pirfenidone gel was evident
with the mLoSSI score, showing an improvement in
87.5% of the treated cases and 100% improvement in
66% at 6 months of treatment (P = 0.002). This result is
comparable to that observed with the application of 5%
imiquimod cream, an interferon γ inductor and TGF-β
inhibitor, with reduction of the skin induration and
thickening in patients with localized scleroderma [15].
However, in the study of Dytoc et al., a subjective
clinical scale was used to determine the changes in the
disease and was not validated to assess the changes in
pigmentation, induration, erythema and telangiectasias,
which makes it difficult to reproduce their results. In
contrast, we used the mLoSSI, a validated method to
assess localized scleroderma with interobserver and
intraobserver agreement of 0.70 and 0.77, respectively,
and sensitivity to change in a 10-week period, making it
a recommended tool for clinical studies as a validated
clinimetric instrument [9].
We additionally demonstrated the usefulness of 8%
pirfenidone gel with the durometer, a handheld device
that quantitatively measures skin hardness. The mea-
surements done with this device are simple, accurate,
valid, objective, precise and sensitive to change [11,16].
Also, in this study, we did measures on control zones,which support the consistency of the observer’s assess-
ment. The mean induration of the localized scleroderma
plaques diminished between the basal and final measure-
ments (35.79 DU vs. 32.47 DU, P = 0.05), showing a ten-
dency toward reduction. We speculate that an increase
in the treatment period with pirfenidone could obtain a
statistically significant reduction.
The Kroft et al. study also showed the effectiveness of
0.1% tacrolimus for the treatment of active localized
scleroderma inflammatory lesions. A significant differ-
ence was found between topical tacrolimus vs. petrol-
atum with respect to the scores for hardness, obtained
using a durometer (P < 0.005) and clinical characteristics
(P = 0.019) [10].
Few authors have included histopathological changes in
their evaluations [15,17]. Our study showed histologic
changes that were in accord with the clinical improve-
ment, showing a statistically significant change in dermal
infiltration (P = 0.034) and fibrosis of reticular dermis (P =
0.039), which could be explained by the anti-inflammatory
and antifibrotic effects of pirfenidone [3,18,19].
The beneficial effects observed for 8% pirfenidone gel
on localized scleroderma plaques may be related to its
reported capacity to inhibit proinflammatory cytokines
levels, as well as to activate interleukin 10 (IL-10) pro-
duction. Clinical effects on inflammation and fibrosis
have been recognized by Carter et al., on idiopathic
pulmonary fibrosis, as well as by Armendariz-Borunda
et al., in skin scarring caused by burns in children
[3,18,20], but this cytokine change was not evaluated in
the present work.
Figure 2 Scleroderma erythema, peeling and fissures remission. (a) Scleroderma plaque with erythema, peeling and fissures. (b) Remission
of the signs with a better state of hydration; only residual hyperpigmentation can be observed.
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scleroderma differs from that observed with other medica-
tions, such as topical tacrolimus, mycophenolate mofetil
and betamethasone dipropionate/calcipotriol, which have
shown effectiveness only in the incipient inflammatory
stages of localized scleroderma [14,21-23]. Additionally,
pirfenidone has an effect on the development of fibro-
sis [7,18,20].
The tolerability observed in the patients in this series
is similar to that reported for topical use in pediatric pa-
tients with scarring secondary to burns [20]. Topical side
effects were minimal and did not require suspending the
medication, and no clinical or laboratorial adverse effects
were observed.
Pirfenidone seems to have specific attributes for the
treatment of localized scleroderma. It has shown antifi-
brotic effects in in vivo and in vitro models, reducing
the production of cytokines such as TGF-β, PDGF, fibro-
blast growth factor β, the deposit and synthesis of col-
lagen, inhibition of the recruitment and/or expression ofextracellular matrix production cells has anti-inflammatory
effects by inhibition of the liberation of proinflammatory
cytokines TNF-α, IL-1β, IL-6, IL-8 and IL-12 and increased
anti-inflammatory cytokines such as IL-10. Also, evidence
exists that pirfenidone suppresses the production or liber-
ation of chemotactic cytokines from inflammatory cells, re-
ducing the accumulation in response to stimuli, and shows
antioxidant effects with improved levels of enzymatic sys-
tems, such as the superoxide dismutase or the myeloperoxi-
dase, along with its capturing effects of free radicals
[3-5,8,18,19]. All these processes could be the mechanisms
that mediated the results obtained in this study.
The limitations of our study include the small number
of patients, the lack of a control group and the short
duration of treatment. In future studies, the follow-up
phase must be prolonged to allow for the definition of
the optimal treatment period and determination whether
8% pirfenidone gel has met the objectives for patients
with localized scleroderma (that is, by improving the le-
sions, delaying their progress and preventing permanent

























1 1 0 100 56.73 49.12 13.41 0 4 −4 0 5 −5
2 3 0 100 35.6 34.51 3.06 0 0 0 0 0 0
3 14 6 57 36.95 38.09 −3.08 7 5 29 0 0 0
4 11 1 93 28.37 30.27 −6.7 8 2 75 7 2.5 65
5 9 0 100 33.71 31.14 7.62 5 3 40 8 3 62
6 3 0 100 26.21 27.03 −3.13 6.5 1.5 77 6.5 2 69
7 2 0 100 32.49 35.39 −8.93 10 4.5 55 5 2.5 50
8 2 1 50 30.23 26.26 13.13 5 3 40 0 0 0
9 4 2 50 45.52 42.02 7.69 7 3 57 5 2 60
10 3 0 100 42.68 35.29 17.31 8 0 100 5 0 100
11 14 0 100 36.83 27.05 26.56 0 0 0 3 0 100
12 4 0 100 24.18 13.51 44.12 3 3 0 8 0 100
Mean 5.83 0.83 NA 35.79 32.47 NA 4.96 2.42 NA 3.96 1.42 NA
P-valueb 0.002 0.05 0.032 0.065
aThe response to pirfenidone is evidenced by improvement in both physician (mLoSSI and durometer units) and patient (hardness of the lesions) evaluations. bWilcoxon rank-sum test. mLoSSI, Modified Localized














Figure 3 Histologic changes before and after treatment. (a) Pretreatment fibrosis, well-defined pockets of perivascular inflammation in the
dermis and subcutaneous cellular tissue. (b) Posttreatment biopsy, collagen loosening of compaction in the superficial and middle reticular
dermis with recovery of the annexes. (c) Masson’s trichromic stain before treatment. (d) Posttreatment biopsy showing the changes described
previously (original magnification, 40×).















Basal Final Basal Final Basal Final Basal Final Basal Final Basalb Finalc Basal Final
Absence 1 4 0 0 4 3 1 3 1 4 2 0 1 1
Light 1 4 4 8 3 9 6 3 4 2 3 3 4 3
Moderate 4 1 5 3 5 0 2 3 1 6 2 1 3 3































P-valued 0.010 0.034 0.305 0.705 0.039 0.276 0.581
aThe microscopic findings showed statistically significant changes in epidermal atrophy, dermal infiltration and reticular dermis fibrosis. bNonevaluable case.
cThree nonevaluable cases. dWilcoxon rank-sum test. SD, Standard deviation.
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that pirfenidone can be a promising therapeutic agent
for localized scleroderma.
Conclusions
This is the first study on the therapeutic use of pirfeni-
done gel in localized scleroderma, showing response
clinically with the mLoSSI, durometer and histological
evidence. Considering its effectiveness, good safety pro-
file and the advantage of topical application, pirfenidone
8% gel is a treatment option in localized scleroderma.
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